Abstract
Heparan sulfate (HS) is present on the surface of endothelial and surrounding tissues in large quantities. It plays important roles in regulating numerous functions of the blood vessel wall, including blood coagulation, inflammation response, and cell differentiation. HS is a highly sulfated polysaccharide containing glucosamine and glucuronic/iduronic acid repeating disaccharide units. The unique sulfated saccharide sequences of HS determine its specific functions. Heparin, an analog of HS, is the most commonly used anticoagulant drug. Because of its wide range of biological functions, HS has become an interesting molecule to biochemists, medicinal chemists, and developmental biologists. In this review, we summarize recent progress toward understanding the interaction between HS and blood-coagulating factors, the biosynthesis of anticoagulant HS and the mechanism of action of HS biosynthetic enzymes. Furthermore, knowledge of the biosynthesis of HS facilitates the development of novel enzymatic approaches to synthesize HS from bacterial capsular polysaccharides and to produce polysaccharide end products with high specificity for the biological target. These advancements provide the foundation for the development of polysaccharide-based therapeutic agents.
Similar content being viewed by others
References
Aikawa J-i, Grobe K, Tsujimoto M, Esko JD (2001) Multiple isozymes of heparan sulfates/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase: structure and activity of the fourth member, NDST4. J Biol Chem 276:5876–5882
Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K (2004) Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 279:12346–12354
Atha DH, Lormeau J-C, Petitou M, Rosenberg RD, Choay J (1985) Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 24:6723–6729
Avci FY, Karst NA, Linhardt RJ (2003) Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr Pharm Des 9:2323–2335
Balagurunathan K, Beeler DL, Lech M, Wu ZL, Rosenberg RD (2003a) Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem 278:52613–52621
Balagurunathan K, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD (2003b) Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat Biotechnol 21:1343–1346
Becker RC (2004) Optimizing heparin compounds: a working construct for future antithrombotic drug development. J Thromb Thrombolysis 18:55–58
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729–777
Burkart MD, Izumi M, Chapman E, Lin C, Wong C (2000) Regeneration of PAPS for the enzymatic synthesis of sulfated oligosaccharides. J Org Chem 65:5565–5574
Chen J, Duncan MB, Carrick K, Pope M, Liu J (2003) Biosynthesis of 3-O-sulfated heparan sulfate: unique substrate specificity of heparan sulfate 3-O-sulfotransferase isoform 5. Glycobiology 13:785–794
Chen J, Avci FY, Muñoz EM, McDowell LM, Chen M, Pedersen LC, Zhang L, Linhardt RJ, Liu J (2005) Enzymatically redesigning of biologically active heparan sulfate. J Biol Chem 280:42817–42825
Coombe DR, Kett WC (2005) Heparan sulfate-protein interactions: therapeutic potential through structure–function insights. Cell Mol Life Sci 62:410–424
Das S, Mallet J, Esnault J, Driguez P, Duchaussoy P, Sizun P, Herault J, Herbert J, Petitou M, Sinay P (2001) Synthesis of conformationally locked L-iduronic acid derivatives: direct evidence for a critical role of the skew-boat 2S0 conformer in the activation of antithrombin by heparin. Chemistry 7:4821–4834
de Paz JL, Noti C, Seeberger PH (2006) Microarrays of synthetic heparin oligosaccharides. J Am Chem Soc 128:2766–2767
Dementiev A, Petitou M, Herbert J-M, Gettins PG (2004) The ternary complex of antithrombin–anhydrothrombin–heparin reveals the basis of inhibitor specificity. Nat Struct Biol 11:867–863
Duncan MB, Chen J, Krise JP, Liu J (2004) The biosynthesis of anticoagulant heparan sulphate by the heparan sulphate 3-O-sulphotransferase isoform 5. Biochim Biophys Acta 1671:34–43
Edavettal SC, Lee KA, Negishi M, Linhardt RJ, Liu J, Pedersen LC (2004) Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem 279:25789–25797
Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435–471
Ferro V, Don R (2003) The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug. Australas Biotechnol 13:38–39
Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102:4751–4803
Habuchi H, Habuchi O, Kimata K (1995) Purification and characterization of heparan sulfate 6-sulfotransferase from the culture medium of Chinese hamster ovary cells. J Biol Chem 270:4172
Habuchi H, Tanaka M, Habuchi O, Yoshida K, Suzuki H, Ban K, Kimata K (2000) The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. J Biol Chem 275:2859–2868
Hacker U, Nybakken K, Perrimon N (2005) Heparan sulfate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 6:530–541
HajMohammadi S, Enjyoji K, Princivalle M, Christi P, Lech M, Beeler DL, Rayburn H, Schwartz JJ, Barzegar S, de Agostini AI, Post MJ, Rosenberg RD, Shworak NW (2003) Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest 111:989–999
Herbert JM, Herault JP, Bernat A, Savi P, Schaeffer P, Driguez PA, Duchaussov P, Petitou M (2001) SR 123781A, a synthetic heparin mimetic. Thromb Haemost 85:852–860
Hirsh J, O’Donnell M, Weitz JI (2005) New anticoagulants. Blood 105:453–463
Ishihara M, Guo Y, Wei Z, Yang Z, Swiedler SJ, Orellana A, Hirschberg CB (1993) Regulation of biosynthesis of the basic fibroblast growth factor binding domains of heparan sulfate by heparan sulfate-N-deacetylase/N-sulfotransferase expression. J Biol Chem 268:20091–20095
Jin L, Abrahams P, Skinner R, Petitou M, Pike RN, Carrell RW (1997) The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94:14683–14688
Kelton JG (2002) Heparin-induced thrombocytopenia: an overview. Blood Rev 16:77–80
Kobayashi M, Habuchi H, Habuchi O, Saito M, Kimata K (1996) Purification and characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary cells. J Biol Chem 271:7645–7653
Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946–950
Kuberan B, Beeler DL, Lawrence R, Lech M, Rosenberg R (2003) Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin. J Am Chem Soc 125:12424–12425
Lee JC, Lu XA, Kulkarni SS, Wen YS, Hung SC (2004) Synthesis of heparin oligosaccharides. J Am Chem Soc 126:476–477
Li W, Johnson DJ, Esmon CT, Huntington JA (2004) Structure of the antithrombin–thrombin–heparin ternary complex reveals the anti-thrombotic mechanism of heparin. Nat Struct Mol Biol 11:857–862
Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K (1998) The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273:26265–26268
Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273:24979–24982
Lindahl U, Li J, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emies J, Roberts I, Taylor C, Oreste P et al (2005) Generation of “neoheparin” from E. Coli K5 capsular polysaccharide. J Med Chem 48:349–352
Liu J, Rosenberg RD (2002) Heparan sulfate D-glucosaminyl 3-O-sulfotransferase. In: N Taniguchi, M Fukuda (eds) Handbook of glycosyltransferases and their related genes. Springer, Berlin Heidelberg New York, pp 475–483
Liu J, Thorp SC (2002) Heparan sulfate and the roles in assisting viral infections. Med Res Rev 22:1–25
Liu J, Shworak NW, Fritze LMS, Edelberg JM, Rosenberg RD (1996) Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 271:27072–27082
Liu J, Shworak NW, Sinaÿ P, Schwartz JJ, Zhang L, Fritze LMS, Rosenberg RD (1999) Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem 274:5185–5192
McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F (1998) The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19:158–161
Merritt EA, Bacon DJ (1997) Raster3D: photorealistic molecular graphics. Methods Enzymol 277:505–524
Mikhailov D, Mayo KH, Pervin A, Linhardt RJ (1996) 13C-NMR relaxation study of heparin–disaccharide interactions with tripeptide GRG and GKG. Biochem J 315:447–454
Moon A, Edavettal SC, Krahn JX, Munoz EM, Negishi M, Linhardt RJ, Liu J, Pedersen LC (2004) Structural analysis of the sulfotransferase (3-OST-3) involved in the biosynthesis of an entry receptor of herpes simplex virus 1. J Biol Chem 279:45185–45193
Mulloy B, Forster M (2000) Conformation and dynamics of heparin and heparan sulfate. Glycobiology 10:1147–1156
Nyberg K, Ekblad M, Bergstrom T, Freeman C, Parish CR, Ferro V, Trybala E (2004) The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antiviral Res 63:15–24
Oosta GM, Gardner WT, Beeler DL, Rosenberg R (1981) Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 78:829–833
Petitou M, van Boeckel CAA (1992) Chemical synthesis of heparin fragments and analogues. Fortschr Chem Org Naturst 60:143–210
Petitou M, van Boeckel CAA (2004) A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed 43:3118–3133
Petitou M, Herault L-P, Bernat A, Driguez P-A, Duchaussoy P, Lormeau J-C, Herbert J-M (1999) Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398:417–422
Raman R, Sasisekharan V, Sasisekharan R (2005) Structural insights into biological roles of protein–glycosaminoglycan interactions. Chem Biol 12:267–277
Rosenberg RD, Showrak NW, Liu J, Schwartz JJ, Zhang L (1997) Heparan sulfate proteoglycans of the cardiovascular system: specific structures emerge but how is synthesis regulated? J Clin Invest 99:2062–2070
Sanderson RD, Yang Y, Suva LJ, Kelly T (2004) Heparan sulfate proteglycans and heparanase—partners in osteolytic tumor growth and metastasis. Matrix Biol 23:341–352
Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparin-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521–528
Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG (1999) A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13–22
Shworak NW, Liu J, Fritze LMS, Schwartz JJ, Zhang L, Logeart D, Rosenberg RD (1997) Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 272:28008–28019
Shworak NW, Liu J, Petros LM, Zhang L, Kobayashi M, Copeland NG, Jenkins NA, Rosenberg RD (1999) Diversity of the extensive heparan sulfate D-glucosaminyl 3-O-sulfotransferase (3-OST) multigene family. J Biol Chem 274:5170–5184
Smeds E, Habuchi H, Do A-T, Hjertson E, Grundberg H, Kimata K, Lindahl U, Kusche-Gullberg M (2003) Substrate specificities of mouse heparan sulphate glucosaminyl 6-O-sulfotransferases. Biochem J 372(Pt 2):371–380
Taylor KR, Gallo RL (2006) Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 20:9–22
Xia G, Chen J, Tiwari V, Ju W, Li J-P, Malmström A, Shukla D, Liu J (2002) Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J Biol Chem 277:37912–37919
Xu D, Tiwari V, Xia G, Clement C, Shukla D, Liu J (2005) Characterization of heparan sulfate 3-O-sulfotransferase isoform 6 and its role in assisting the entry of herpes simplex virus, type 1. Biochem J 385:451–459
Acknowledgements
The authors are grateful to A.F. Moon and Dr. L.G. Pedersen for critical reading of the manuscript. The Liu lab is supported by a grant from the National Institutes of Health (AI050050). This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, J., Pedersen, L.C. Anticoagulant heparan sulfate: structural specificity and biosynthesis. Appl Microbiol Biotechnol 74, 263–272 (2007). https://doi.org/10.1007/s00253-006-0722-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-006-0722-x